通用環球醫療集團有限公司 GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承 擔任何責任。 本公告乃由通用環球醫療集團有限公司（「本公司」）根據香港聯合交易所有限公司證券上 市規則（「上市規則」）第13.09(2)(a)條及香港法例第571章證券及期貨條例第XIVA部內幕 消息條文（定義見上市規則）作出。 茲提述本公司於二零二五年八月五日刊發的公告（「該公告」），內容有關本公司的全資附 屬公司中國環球租賃有限公司（「發行人」）在中華人民共和國（「中國」）境內發行二零 二五年第二期可續期公司債券（「本期公司債」）。除非文義另有所指，本公告所用詞與該 公告所界定者具有相同含義。 本公司欣然宣佈本期公司債已於二零二五年八月八日在中國完成發行。已發行的本期公司債 本金總額為人民幣5.50億元，自二零二五年八月八日起基礎期限為3年，固定利率為2.35%。 在約定的基礎期限末及每個續 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年7月31日 | 狀態: | 新提交 | | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | 公司名稱: | 通用環球醫療集團有限公司 | | | | 呈交日期: | 2025年8月6日 | | | | I. 法定/註冊股本變動 不適用 | | | | | 備註： | | | | | 因公司註冊成立於香港，故法定股本及註冊股本的概念並不適用。 | | | | 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02666 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | ...

| 指标 | 环球医疗 | 医疗服务 行业平均 | 行业排名 | | --- | --- | --- | --- | | ROE | 12.68% | -2.25% | 8 60 | | 港股流通市值 | 118.79亿 | 68.55 乙 | 5 60 | | 营业收入 | 136.63亿 | 37.04亿 | 4 60 | | 净利率 | 16.53% | -841.37% | a 60 | | 毛利率 | 33.61% | 36.84% | 27 60 | | 负债率 | 73.42% | 73.74% | 51 60 | 环球医疗(02666.HK)发布公告，公司的全资附属公司中国环球租赁有限公司(发行人)已得到中国证券监 督管理委员会批复核准，在中国面向合格投资者公开发行本金总额最高达人民币20亿元的境内可续期公 司债，截至本公告日期剩余额度为人民币12亿元。该债券采用分期方式发行，本次债券发行本金总额不 超过人民币8.5亿元(含人民币8.5亿元)。本期公司债的基础期限为3年期。 截至2025年8月5日收盘，环球医疗(02666.HK)报收于6.2港元，下跌1.27%，成交量1864.25万股，成交 ...

本期公司债以和其基础期限相等的期限为1个重定价周期，在约定的基础期限及每个重定价周期末，发 行人有权选择将本次债券期限延长1个重定价周期，或全额兑付本次债券。本期公司债附有发行人续期 选择权、发行人递延支付利息权、发行人赎回选择权。发行利率在首个周期内固定不变，并将于截止认 购申请时通过簿记建档方式最终厘定，票面利率为初始基准利率加上初始利差，其后每个周期重置一 次，后续周期的票面利率调整为当期基准利率加上初始利差再加300个基点。发行本期公司债的净额收 益将由发行人用作补充运营资金。 环球医疗(02666)发布公告，公司的全资附属公司中国环球租赁有限公司(发行人)已得到中国证券监督管 理委员会批复核准，在中国面向合格投资者公开发行本金总额最高达人民币20亿元的境内可续期公司 债，截至本公告日期剩余额度为人民币12亿元。该债券采用分期方式发行，本次债券发行本金总额不超 过人民币8.5亿元(含人民币8.5亿元)。本期公司债的基础期限为3年期。 ...

Core Viewpoint - The company, Global Medical (02666), has received approval from the China Securities Regulatory Commission to publicly issue a maximum of RMB 2 billion in domestic renewable corporate bonds aimed at qualified investors, with a remaining quota of RMB 1.2 billion as of the announcement date [1] Group 1: Bond Issuance Details - The bond will be issued in tranches, with the total principal amount not exceeding RMB 850 million [1] - The basic term of the corporate bond is set at 3 years, with the issuer having the option to extend the term by one repricing cycle or fully redeem the bond at the end of the basic term and each repricing cycle [1] - The bond includes options for the issuer to extend the term, defer interest payments, and redeem the bond [1] Group 2: Interest Rate Structure - The interest rate for the first cycle will remain fixed and will be determined through a book-building process at the time of subscription [1] - The coupon rate is set as the initial benchmark rate plus an initial spread, with subsequent cycles resetting the coupon rate to the current benchmark rate plus the initial spread plus an additional 300 basis points [1] Group 3: Use of Proceeds - The net proceeds from the bond issuance will be used by the issuer to supplement operational funds [1]

Core Viewpoint - Global Medical (02666.HK) has received approval from the China Securities Regulatory Commission to publicly issue a maximum of RMB 2 billion in domestic perpetual corporate bonds aimed at qualified investors, with a remaining quota of RMB 1.2 billion as of the announcement date [1] Group 1 - The bond issuance will be conducted in tranches, with the total principal amount for this issuance not exceeding RMB 850 million [1] - The basic term of the corporate bond is set at 3 years, with the issuer having the option to extend the term by one repricing cycle or fully redeem the bond at the end of the agreed term and each repricing cycle [1] - The bond includes options for the issuer to extend the term, defer interest payments, and redeem the bond [1] Group 2 - The interest rate for the first cycle will remain fixed and will be determined through a book-building process at the time of subscription, with the coupon rate set as the initial benchmark rate plus an initial spread [1] - Subsequent cycles will see the coupon rate adjusted to the current benchmark rate plus the initial spread plus an additional 300 basis points [1] - The net proceeds from this bond issuance will be used by the issuer to supplement operational funds [1]

於中國境內公開發行二零二五年第二期可續期公司債券的公告 本公告乃由通用環球醫療集團有限公司（「本公司」）根據香港聯合交易所有限公司證券上 市規則（「上市規則」）第13.09(2)(a)條及香港法例第571章證券及期貨條例第XIVA部內幕 消息條文（定義見上市規則）作出。 本公司的全資附屬公司中國環球租賃有限公司（「發行人」）已得到中國證券監督管理委員 會（「中證監」）批復核准，在中華人民共和國（「中國」）面向合格投資者公開發行本金 總額最高達人民幣 20 億元的境內可續期公司債，截至本公告日期剩餘額度為人民幣 12 億元。 該債券採用分期方式發行，本次債券（「本期公司債」）發行本金總額不超過人民幣 8.5 億 元（含人民幣 8.5 億元）。本期公司債的基礎期限爲 3 年期。本期公司債以和其基礎期限相 等的期限為 1 個重定價周期，在約定的基礎期限及每個重定價周期末，發行人有權選擇將本 次債券期限延長 1 個重定價周期，或全額兌付本次債券。本期公司債附有發行人續期選擇權、 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不對因本公告全部 ...

Core Insights - Universal Medical Group Limited celebrates its 10th anniversary on the Hong Kong Stock Exchange, evolving from a medical financial service provider to a comprehensive healthcare service supplier with a focus on "financial services + comprehensive medical care + specialized medical care + health technology" [1][2] - Over the past decade, the company's revenue increased from 1.55 billion to 13.66 billion, with a compound annual growth rate (CAGR) of 22.5%, and total assets grew from 16.39 billion to 86.03 billion, with a CAGR of 18.0% [1] - The company has maintained a 30% dividend payout ratio for ten consecutive years, distributing over 4.5 billion in dividends, significantly exceeding the total amount raised during its IPO [1] Business Development - Since its listing in 2015, Universal Medical has expanded from its medical finance roots into the core healthcare industry, establishing a strategic framework that emphasizes medical services, supported by financial services and driven by health technology [2] - The company has provided over 200 billion in financing support to more than 2,000 clients, holding two AAA-rated credit entities and securing significant credit resources from financial institutions [2] - Universal Medical operates nearly 70 medical institutions across 14 provinces in China, with over 16,000 beds and serving more than 10 million patients annually [2] Industry Positioning - The company has extended its healthcare industry chain by developing a full-cycle management service for medical equipment and a smart healthcare service brand, managing assets exceeding 37 billion in medical equipment [3] - Universal Medical aims to align with national strategies by providing innovative financial solutions, enhancing medical service quality, and leveraging digital health technology to support the development of the elderly economy and the health of the Chinese population [3]

Group 1 - The core viewpoint of the article highlights that Universal Medical has been awarded the "Best ESG Solution" at The Asset's 2025 Treasurise Awards for its outstanding practices in sustainable finance, particularly in sustainable-linked risk hedging transactions [1] - The sustainable financial solution recognized was a collaboration between Universal Medical and OCBC Group, which involved the issuance of 200 million yuan in green loans and 400 million yuan in syndicated loans aimed at financing green photovoltaic renewable energy projects [1][3] - Universal Medical's commitment to sustainable development is reflected in its diverse range of sustainable financial products, including green syndicated loans, ESG-linked corporate bonds, and sustainable-linked asset securitization products, with a total green credit scale reaching 7.053 billion yuan and sustainable bond issuance of 2.477 billion yuan [3][4] Group 2 - The Asset magazine is recognized as one of the most authoritative English media outlets in Asia's investment community, focusing on corporate treasury management, trade financing, supply chain management, and risk management [4] - The awards process conducted by The Asset is characterized by its transparency, independence, and rigor, utilizing questionnaires and client interviews to evaluate financial transactions in the Asian region [4]

Core Viewpoint - The company has shown steady operational improvement in Q1 2025, with significant increases in revenue and profit compared to the same period last year Group 1: Financial Performance - The company's revenue increased by approximately 16.1% year-on-year for the three months ending March 31, 2025, while profit rose by about 14.3% [1] - Profit attributable to ordinary shareholders increased by approximately 16.7% compared to the same period last year [1] Group 2: Comprehensive Medical Services - The company has focused on improving the quality and efficiency of comprehensive medical services amidst external challenges such as payment reforms and strict management of medical insurance funds [1] - The overall operational status of the company's medical institutions was good, with outpatient and emergency visits increasing by about 2.3% year-on-year [1] - The average length of hospital stay decreased to 9.2 days, indicating improved operational efficiency [1] - Medical service revenue accounted for 35.6% of total revenue, up by 2.5 percentage points year-on-year, reflecting an optimized revenue structure [1] - The proportion of drug costs to revenue decreased from 46.5% to 43.7%, demonstrating effective cost control [1] Group 3: Specialized Medical and Health Technology - The company is pursuing a dual strategy of intrinsic development and external expansion in specialized medical and health technology [2] - The acquisition of Beijing Jinxu Medical Instrument Co., Ltd. was completed, enhancing the company's capabilities in medical endoscopy and related services [2] - This acquisition addresses challenges related to high asset values and maintenance costs in the company's managed services for medical endoscopes [2] - The company has expanded its market presence and improved its integration with regional governments following the acquisition of Shandong Qingniao Soft Communication Co., Ltd. [2] Group 4: Financial Business - The company is committed to serving the real economy and advancing its financial business transformation [3] - It is transitioning towards four key areas: health and wellness, equipment manufacturing, chemical pharmaceuticals, and innovative businesses [3] - The company has introduced a new model combining "financing leasing + full lifecycle management" for medical equipment [3] - The company has effectively controlled overall financing costs while ensuring adequate liquidity and stable debt structure [3] - As of March 31, 2025, the total interest-earning assets have continued to grow, with stable improvements in net interest margin and net profit margin [3]